Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.

@article{Mariette2015EfficacyAS,
  title={Efficacy and safety of belimumab in primary Sj{\"o}gren's syndrome: results of the BELISS open-label phase II study.},
  author={Xavier Mariette and Rapha{\'e}le Seror and Luca Quartuccio and Gabriel Baron and Sara Salvin and Martina Fabris and Fr{\'e}d{\'e}ric Desmoulins and Ga{\'e}tane Nocturne and Philippe Ravaud and Salvatore de Vita},
  journal={Annals of the rheumatic diseases},
  year={2015},
  volume={74 3},
  pages={526-31}
}
BACKGROUND Increased expression of B cell activating factor (BAFF or B lymphocyte stimulator) may explain the B cell activation characteristic of primary Sjögren's syndrome (pSS). OBJECTIVES To evaluate the efficacy and safety of belimumab, targeting BAFF, in patients with pSS. METHODS Patients were included in this bi-centric prospective 1-year open-label trial if they fulfilled American European Consensus group criteria, were anti-Sjögren's syndrome A-positive and had current systemic… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 35 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Tolerance and ef fi cacy of Rituximab in primary Sjögren ’ s syndrome ( TEARS ) : Results of a randomized controlled trial

V Devauchelle-Pensec, X Mariette, S Jousse-Joulin
Ann Rheum Dis • 2012

Similar Papers

Loading similar papers…